ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly.
… Investor/Analyst Webcast: Lilly Partnership Expansion and Axiomer Overview ProQR Management will host an investor … conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the … 30 days following the presentation date. About Axiomer ® ProQR is pioneering a next-generation RNA base …
On March 29, 2023 ProQR will host a virtual R&D event to showcase its proprietary Axiomer RNA-editing technology platform. ProQR will also announce initial pipeline targets for internal development.
… ProQR Therapeutics Date: Thursday, March 23 Abstract: Axiomer, an RNA editing platform, uses chemically modified … and the presentation will review the potential of Axiomer platform in multiple organs as well as its …
ProQR shared additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company strategy. Management to host a conference call today at 8:00am EDT (14:00 CET).
… P-705: “ Robust and Durable RNA Editing In Vivo with Axiomer™ Editing Oligonucleotides in Non-Human Primates ” … - 23:59 ProQR will present new preclinical data for Axiomer, including the first preclinical data for its AX-0810 …
ProQR will host a virtual Analyst and Investor Event on Wednesday, December 11, 2024 from 10:00 am until approximately 12:30 pm EST, including an Analyst Q&A session with members of the ProQR Management Team.